Flavopiridol in Treating Patients With Recurrent Prostate Cancer

Phase 2 Completed 40 enrolled National Cancer Institute (NCI)

NaSingle-groupOpen-labelTreatment

Summary

Phase II trial to study the effectiveness of flavopiridol in treating patients with recurrent prostate cancer after hormone therapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Timeline

Start: 1998-05
Primary completion: 2002-07
Completion: 2004-04

Outcome

Missed primary endpoint

paper as only 3 of 22 (14%) of the patients met the 6-month progression-free survival end point. PMID 14871968 ↗

Publications

Results Liu G, Gandara DR, Lara PN Jr, Raghavan D, Doroshow JH, Twardowski P, Kantoff P, Oh W, Kim K, Wilding G. A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin Cancer Res. 2004 Feb 1;10(3):924-8. doi: 10.1158/1078-0432.ccr-03-0050.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	alvocidib	Small molecule	40 mg/m2	Intravenous
Subject	alvocidib	Small molecule	60 mg/m2	Intravenous